ID   DOGUM
AC   CVCL_2024
SY   DoGum
DR   BioSample; SAMN03473458
DR   DepMap; ACH-001493
DR   DSMZ; ACC-644
DR   DSMZCellDive; ACC-644
DR   Wikidata; Q54831346
RX   PubMed=17562080;
RX   PubMed=26727417;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Virology: EBV-negative.
CC   Doubling time: ~50 hours, ~100 hours (Note=After recovery from liquid nitrogen freezing) (DSMZ=ACC-644).
CC   Miscellaneous: Originally assigned to be from a B-cell non-Hodgkin lymphoma, centroblastic-type.
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
CC   Cell type: B-cell; CL=CL_0000236.
ST   Source(s): DSMZ=ACC-644
ST   Amelogenin: X
ST   CSF1PO: 11,12
ST   D13S317: 8
ST   D16S539: 11,12
ST   D18S51: 13,16
ST   D19S433: 14,16
ST   D21S11: 29,30
ST   D2S1338: 25
ST   D3S1358: 16,17
ST   D5S818: 12
ST   D7S820: 11,12
ST   D8S1179: 13,14
ST   FGA: 21
ST   Penta D: 9
ST   Penta E: 12,17
ST   TH01: 9,9.3
ST   TPOX: 11
ST   vWA: 16,17
DI   NCIt; C7954; Adult Burkitt leukemia
DI   ORDO; Orphanet_543; Burkitt lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   49Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 21
//
RX   PubMed=17562080; DOI=10.1007/s00432-007-0241-x;
RA   Bracht K., Kiefer T., Dolken G., Bednarski P.J.;
RT   "Characterization of three B-cell lymphoma cell lines from
RT   chemotherapy resistant patients with respect to in vitro sensitivity
RT   to 21 antitumor agents, ABC-transporter expression and cellular redox
RT   status.";
RL   J. Cancer Res. Clin. Oncol. 133:957-967(2007).
//
RX   PubMed=26727417; DOI=10.3109/10428194.2015.1108414;
RA   Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.;
RT   "Malignant hematopoietic cell lines: in vitro models for double-hit
RT   B-cell lymphomas.";
RL   Leuk. Lymphoma 57:1015-1020(2016).
//